1 OS‐overall analysis |
6 |
2171 |
Hazard Ratio (Fixed, 95% CI) |
0.98 [0.89, 1.08] |
2 OS‐sensitivity analysis by random‐effects model |
6 |
2171 |
Hazard Ratio (Random, 95% CI) |
0.97 [0.83, 1.12] |
3 OS‐sensitivity analysis by excluding studies with high risk of bias |
5 |
2115 |
Hazard Ratio (Fixed, 95% CI) |
1.01 [0.92, 1.11] |
4 OS‐subgroup analysis by dose of IDA |
6 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
4.1 8 mg/m²/d |
2 |
220 |
Hazard Ratio (Fixed, 95% CI) |
1.06 [0.81, 1.39] |
4.2 10 mg/m²/d |
2 |
1663 |
Hazard Ratio (Fixed, 95% CI) |
0.99 [0.89, 1.11] |
4.3 12 mg/m²/d |
2 |
288 |
Hazard Ratio (Fixed, 95% CI) |
0.90 [0.73, 1.11] |
5 OS‐subgroup analysis by age |
2 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
5.1 ≥ 15 years to < 60 years |
1 |
1436 |
Hazard Ratio (Fixed, 95% CI) |
0.99 [0.88, 1.11] |
5.2 ≥ 60 years |
1 |
160 |
Hazard Ratio (Fixed, 95% CI) |
1.03 [0.75, 1.41] |
6 DFS‐overall analysis |
4 |
249 |
Hazard Ratio (Fixed, 95% CI) |
0.88 [0.70, 1.10] |
7 DFS‐sensitivity analysis by random‐effects model |
4 |
249 |
Hazard Ratio (Random, 95% CI) |
0.86 [0.62, 1.21] |
8 DFS‐subgroup analysis by dose of IDA |
4 |
|
Hazard Ratio (Fixed, 95% CI) |
Subtotals only |
8.1 8 mg/m²/d |
2 |
123 |
Hazard Ratio (Fixed, 95% CI) |
1.06 [0.75, 1.50] |
8.2 12 mg/m²/d |
2 |
126 |
Hazard Ratio (Fixed, 95% CI) |
0.75 [0.55, 1.02] |
9 CR‐overall analysis |
8 |
2411 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.92, 1.03] |
10 CR‐sensitivity analysis by random‐effects model |
8 |
2411 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.92, 1.02] |
11 CR‐subgroup analysis by dose of IDA |
6 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
11.1 8 mg/m²/d |
2 |
220 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.70, 1.11] |
11.2 10 mg/m²/d |
2 |
1663 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.90, 1.02] |
11.3 12 mg/m²/d |
2 |
295 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.80, 1.24] |
12 CR‐subgroup analysis by age |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
12.1 ≥ 15 years to < 60 years |
2 |
1490 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.90, 1.03] |
12.2 ≥ 60 years |
2 |
169 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.71, 1.18] |
13 Death on induction therapy‐overall analysis |
5 |
2055 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.10 [0.88, 1.38] |
14 Death on induction therapy‐sensitivity analysis by random‐effects model |
5 |
2055 |
Risk Ratio (M‐H, Random, 95% CI) |
1.10 [0.88, 1.38] |
15 Death on induction therapy‐subgroup analysis by dose of IDA |
4 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
15.1 8 mg/m²/d |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.8 [0.33, 1.92] |
15.2 10 mg/m²/d |
1 |
1436 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.81, 1.38] |
15.3 12 mg/m²/d |
2 |
295 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.48 [0.90, 2.43] |
16 Death on induction therapy‐subgroup analysis by age |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
16.1 ≥ 15 years to < 60 years |
1 |
1436 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.06 [0.81, 1.38] |
16.2 ≥ 60 years |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.8 [0.33, 1.92] |
17 Relapse‐overall analysis |
3 |
328 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.99 [0.80, 1.22] |
18 Relapse‐sensitivity analysis by random‐effects model |
3 |
328 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.80, 1.19] |
19 Relapse‐subgroup analysis by dose of IDA |
3 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
19.1 8 mg/m²/d |
1 |
95 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.07 [0.75, 1.53] |
19.2 10 mg/m²/d |
1 |
187 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.68, 1.37] |
19.3 12 mg/m²/d |
1 |
46 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.91 [0.66, 1.26] |
20 Nausea/vomiting grade 3/4‐overall analysis |
3 |
387 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.66, 1.61] |
21 Nausea/vomiting grade 3/4‐sensitivity analysis by random‐effects model |
3 |
387 |
Risk Ratio (M‐H, Random, 95% CI) |
1.04 [0.67, 1.63] |
22 Nausea/vomiting grade 3/4‐subgroup analysis by dose of IDA |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
22.1 8 mg/m²/d |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.8 [0.22, 2.87] |
22.2 12 mg/m²/d |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.13, 5.68] |
23 Diarrhoea grade 3/4‐overall analysis |
2 |
223 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.41 [0.68, 2.89] |
24 Diarrhoea grade 3/4‐sensitivity analysis by random‐effects model |
2 |
223 |
Risk Ratio (M‐H, Random, 95% CI) |
1.40 [0.68, 2.88] |
25 Diarrhoea grade 3/4‐subgroup analysis by dose of IDA |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
25.1 8 mg/m²/d |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.33 [0.60, 2.99] |
25.2 12 mg/m²/d |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.71 [0.34, 8.65] |
26 Hepatic toxicity grade 3/4‐overall analysis |
2 |
324 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.22 [0.47, 3.17] |
27 Hepatic toxicity grade 3/4‐sensitivity analysis by random‐effects analysis |
2 |
324 |
Risk Ratio (M‐H, Random, 95% CI) |
1.21 [0.47, 3.16] |
28 Renal toxicity grade 3/4‐overall analysis |
2 |
223 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.31 [0.03, 2.91] |
29 Renal toxicity grade 3/4‐sensitivity analysis by random effects model |
2 |
223 |
Risk Ratio (M‐H, Random, 95% CI) |
0.31 [0.03, 2.91] |
30 Renal toxicity grade 3/4‐subgroup analysis by dose of IDA |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
30.1 8 mg/m²/d |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.33 [0.01, 8.06] |
30.2 12 mg/m²/d |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.01, 6.76] |
31 Mucositis grade 3/4‐overall analysis |
2 |
223 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.89 [0.36, 9.92] |
32 Mucositis grade 3/4‐sensitivity analysis by random‐effects model |
2 |
223 |
Risk Ratio (M‐H, Random, 95% CI) |
1.81 [0.32, 10.21] |
33 Mucositis grade 3/4‐subgroup analysis by dose of IDA |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
33.1 8 mg/m²/d |
1 |
160 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.0 [0.32, 28.23] |
33.2 12 mg/m²/d |
1 |
63 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.85 [0.06, 13.04] |
34 Infection grade 3/4‐overall analysis |
2 |
1663 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.04 [0.91, 1.19] |
35 Infection grade 3/4‐sensitivity analysis by random‐effects analysis |
2 |
1663 |
Risk Ratio (M‐H, Random, 95% CI) |
1.16 [0.78, 1.72] |